No other publication monitors the FDA offices and divisions that review your products more closely than the U.S. Regulatory Reporter. We give you a steady flow of hard regulatory information, one-on-one interview with CDER's review division directors, the latest regulatory statistics, and in-depth analysis on emerging issues and processes associated with drug development and approval.
In each monthly issue, the U.S. Regulatory Reporter provides the information you need to benchmark your own regulatory activities, and to gear your regulatory strategies to address emerging FDA issues and concerns.
From IND reform to regulatory performance benchmarking, and from accelerated drug review case studies to ANDAs, the U.S. Regulatory Reporter gives you the issues before they become issues. Each month, you'll be brought face-to-face with the people and issues most critical to you and your company's products.
Includes 2 year subscription and shipping costs to addresses in Europe.